From the Leeds Institute of Medical Research (J.Z., A.S., A.H.) and Department of Biomedical Imaging (D.B.), University of Leeds, 6 Clarendon Way, Woodhouse, Leeds LS2 9LH, England; Leeds Cancer Centre, St James's University Hospital, Leeds, England (J.Z., A.S., A.H.); Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany (M.K.); Radiation Therapy Research Group (M.K., P.M., A.D., C.E., M.D., P.H., A.C.) and Division of Cancer Sciences (D.M.), University of Manchester, Manchester, England; and The Christie NHS Foundation Trust, Manchester, England (P.M., C.E., M.D., D.M., P.H., A.C.).
Radiographics. 2023 Nov;43(11):e230052. doi: 10.1148/rg.230052.
Radiation therapy (RT) is a core pillar of oncologic treatment, and half of all patients with cancer receive this therapy as a curative or palliative treatment. The recent integration of MRI into the RT workflow has led to the advent of MRI-guided RT (MRIgRT). Using MRI rather than CT has clear advantages for guiding RT to pelvic tumors, including superior soft-tissue contrast, improved organ motion visualization, and the potential to image tumor phenotypic characteristics to identify the most aggressive or treatment-resistant areas, which can be targeted with a more focal higher radiation dose. Radiologists should be familiar with the potential uses of MRI in planning pelvic RT; the various RT techniques used, such as brachytherapy and external beam RT; and the impact of MRIgRT on treatment paradigms. Current clinical experience with and the evidence base for MRIgRT in the settings of prostate, cervical, and bladder cancer are discussed, and examples of treated cases are illustrated. In addition, the benefits of MRIgRT, such as real-time online adaptation of RT (during treatment) and interfraction and/or intrafraction adaptation to organ motion, as well as how MRIgRT can decrease toxic effects and improve oncologic outcomes, are highlighted. MRIgRT is particularly beneficial for treating mobile pelvic structures, and real-time adaptive RT for tumors can be achieved by using advanced MRI-guided linear accelerator systems to spare organs at risk. Future opportunities for development of biologically driven adapted RT with use of functional MRI sequences and radiogenomic approaches also are outlined. RSNA, 2023 Quiz questions for this article are available in the supplemental material.
放射治疗(RT)是肿瘤治疗的核心支柱,一半的癌症患者接受这种治疗作为治愈或姑息治疗。最近将 MRI 整合到 RT 工作流程中,导致了 MRI 引导的 RT(MRIgRT)的出现。与 CT 相比,使用 MRI 引导 RT 对盆腔肿瘤具有明显的优势,包括更好的软组织对比度、改善器官运动可视化,以及有可能对肿瘤表型特征进行成像以识别最具侵袭性或治疗抵抗的区域,从而可以用更集中、更高的辐射剂量进行靶向治疗。放射科医生应该熟悉 MRI 在计划盆腔 RT 中的潜在用途;各种 RT 技术的应用,如近距离治疗和外部束 RT;以及 MRIgRT 对治疗模式的影响。本文讨论了 MRIgRT 在前列腺癌、宫颈癌和膀胱癌中的当前临床应用经验和证据基础,并举例说明了治疗病例。此外,还强调了 MRIgRT 的益处,如在线实时 RT 自适应(治疗期间)和分次内或分次间适应器官运动,以及 MRIgRT 如何降低毒性作用和改善肿瘤学结果。MRIgRT 特别有益于治疗移动性盆腔结构,并且可以通过使用先进的 MRI 引导的直线加速器系统来保护危险器官,实现肿瘤的实时自适应 RT。还概述了使用功能 MRI 序列和放射基因组学方法进行生物驱动的适应性 RT 开发的未来机会。RSNA,2023 本文的测验问题可在补充材料中找到。